Cancer Research and Treatment

Original Articles

Gastrointestinal cancer

Stereotactic Ablative Radiotherapy versus Surgery in Patients with Pulmonary Metastases from Colorectal Cancer: Byung min Lee, Ha Eun Kim, Young Ho Yang, Seung Yoon Yang, Han Sang Kim, Seo Hee Choi, Woong Sub Koom, Byung Jo Park, Jee Suk Chang; Cancer Res Treat. 2025;57(4):1135-1143. Published online February 6, 2025; DOI: https://doi.org/10.4143/crt.2024.1040

Abstract PDF Supplementary Material PubReader ePub

Purpose
We compared the local control rate and toxicity of stereotactic ablative radiotherapy (SABR) versus wedge resection for colorectal pulmonary metastases.
Materials and Methods
We retrospectively reviewed medical charts and imaging of patients treated with SABR or wedge resection between 2010 and 2017 at a single institution.
Results
A total of 404 patients were treated with local therapy for 528 pulmonary metastatic lesions. While surgery was frequently used upfront for smaller, solitary metastases without other site involvement, SABR was often used for larger, multiple lesions and disease burdens beyond the lungs. The 3-year local control rate was 88.6% following surgery, which was not significantly different from that with SABR at 86.7% (p=0.174). No major postoperative complications or mortality were observed in the surgery group, and 2.8% of patients in the SABR group experienced grade 3-4 radiation pneumonitis.
Conclusion
SABR was used in patients with a higher risk of progression compared to those undergoing surgery, yet it has similar local control rates to wedge resection.

Citations

Citations to this article as recorded by

Percutaneous Cryoablation Under Local Anesthesia for Pulmonary Metastases From Colorectal Cancer: Long‐Term Outcomes From a Single‐Institution Retrospective Cohort
Shun Yorimori, Kaoru Kaseda, Yusuke Aoki, Kosuke Sugino, Takahiro Suzuki, Yu Okubo, Shigeki Suzuki, Kyohei Masai, Masashi Tamura, Masanori Inoue, Hideki Yashiro, Seishi Nakatsuka, Yoshikane Yamauchi, Yotaro Izumi, Masafumi Kawamura, Masahiro Jinzaki, Keis
Cancer Reports.2026;[Epub] CrossRef
Emerging Applications of Stereotactic Ablative Radiotherapy in Oligometastatic Colorectal Cancer
Hasan Al-Sattar, Esele Okondo, Amir Mashia Jaafari, Inesh Sood, Jakob Hassan Dinif, Su Yin Lim, Charlotte Hafkamp, Irene Chong, Joao R. Galante, Sola Adeleke
International Journal of Molecular Sciences.2025; 26(21): 10302. CrossRef

3,918 View
197 Download
2 Web of Science
2 Crossref

Genitourinary cancer

Optimal Definition of Biochemical Recurrence in Patients Who Receive Salvage Radiotherapy Following Radical Prostatectomy for Prostate Cancer: Sung Uk Lee, Jae-Sung Kim, Young Seok Kim, Jaeho Cho, Seo Hee Choi, Taek-Keun Nam, Song Mi Jeong, Youngkyong Kim, Youngmin Choi, Dong Eun Lee, Won Park, Kwan Ho Cho; Cancer Res Treat. 2022;54(4):1191-1199. Published online December 7, 2021; DOI: https://doi.org/10.4143/crt.2021.985

Abstract PDF Supplementary Material PubReader ePub

Purpose
This study proposed the optimal definition of biochemical recurrence (BCR) after salvage radiotherapy (SRT) following radical prostatectomy for prostate cancer.
Materials and Methods
Among 1,117 patients who had received SRT, data from 205 hormone-naïve patients who experienced post-SRT prostate-specific antigen (PSA) elevation were included in a multi-institutional database. The primary endpoint was to determine the PSA parameters predictive of distant metastasis (DM). Absolute serum PSA levels and the prostate-specific antigen doubling time (PSA-DT) were adopted as PSA parameters.
Results
When BCR was defined based on serum PSA levels ranging from 0.4 ng/mL to nadir+2.0 ng/mL, the 5-year probability of DM was 27.6%-33.7%. The difference in the 5-year probability of DM became significant when BCR was defined as a serum PSA level of 0.8 ng/ml or higher (1.0-2.0 ng/mL). Application of a serum PSA level of ≥ 0.8 ng/mL yielded a c-index value of 0.589. When BCR was defined based on the PSA-DT, the 5-year probability was 22.7%-39.4%. The difference was significant when BCR was defined as a PSA-DT ≤ 3 months and ≤ 6 months. Application of a PSA-DT ≤ 6 months yielded the highest c-index (0.660). These two parameters complemented each other; for patients meeting both PSA parameters, the probability of DM was 39.5%-44.5%; for those not meeting either parameter, the probability was 0.0%-3.1%.
Conclusion
A serum PSA level > 0.8 ng/mL was a reasonable threshold for the definition of BCR after SRT. In addition, a PSA-DT ≤ 6 months was significantly predictive of subsequent DM, and combined application of both parameters enhanced predictability.

Citations

Citations to this article as recorded by

Effects of silybin on triptorelin-induced bone metabolic abnormalities in prostate cancer revealed based on TMT-based proteomics
Jianhui Li, Xuejiao Lv, Ying Jiang, Sudarshan Kasireddy
PLOS One.2026; 21(1): e0341064. CrossRef
New Prostate MRI Scoring Systems (PI-QUAL, PRECISE, PI-RR, and PI-FAB): AJR Expert Panel Narrative Review
Adriano B. Dias, Silvia D. Chang, Fiona M. Fennessy, Soleen Ghafoor, Sangeet Ghai, Valeria Panebianco, Andrei S. Purysko, Francesco Giganti
American Journal of Roentgenology.2025;[Epub] CrossRef
Biochemical recurrence after radical prostatectomy and postoperative radiotherapy: current evidence and controversial issues
Mattia Longoni, Fabian Falkenbach, Markus Graefen, Tobias Maurer, Pierre I. Karakiewicz, Francesco Montorsi, Alberto Briganti, Giorgio Gandaglia
Current Opinion in Urology.2025; 35(5): 510. CrossRef
Radiation Therapy for Local or Biochemical Recurrence Following Radical Prostatectomy in Patients with Prostate Cancer
Hiroki Nishiyama, Gen Kawaguchi, Kozue Ito, Go Hasegawa, Yohei Ikeda, Noboru Hara, Tsutomu Nishiyama
Research and Reports in Urology.2025; Volume 17: 327. CrossRef
Prostate-specific Antigen Nadir and Time to Nadir Predict Recurrence in Postprostatectomy Patients Treated with Salvage Radiotherapy Without Androgen Deprivation Therapy
Federico Mastroleo, Riccardo Villa, Mattia Zaffaroni, Maria Giulia Vincini, Ciro Franzese, Luca Nicosia, Fabio Matrone, Alessandra Donofrio, Alessandro Magli, Luca Triggiani, Salvina Barra, Giorgia Timon, Matteo Augugliaro, Vincenzo Burgio, Giulio Francol
European Urology Oncology.2025;[Epub] CrossRef
A Prospective Randomized Multicenter Study on the Impact of [18F]F-Choline PET/CT Versus Conventional Imaging for Staging Intermediate- to High-Risk Prostate Cancer
Laura Evangelista, Fabio Zattoni, Marta Burei, Daniele Bertin, Eugenio Borsatti, Tanja Baresic, Mohsen Farsad, Emanuela Trenti, Mirco Bartolomei, Stefano Panareo, Luca Urso, Giuseppe Trifirò, Elisabetta Brugola, Franca Chierichetti, Davide Donner, Lucia S
Journal of Nuclear Medicine.2024; 65(7): 1013. CrossRef
Comparison of the Effects of DOTA and NOTA Chelators on 64Cu-Cudotadipep and 64Cu-Cunotadipep for Prostate Cancer
Inki Lee, Min Hwan Kim, Kyongkyu Lee, Keumrok Oh, Hyunwoo Lim, Jae Hun Ahn, Yong Jin Lee, Gi Jeong Cheon, Dae Yoon Chi, Sang Moo Lim
Diagnostics.2023; 13(16): 2649. CrossRef

10,428 View
186 Download
6 Web of Science
7 Crossref

First
Prev
Page of 1
Next
Last

Search